333 related articles for article (PubMed ID: 15257942)
1. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
3. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
Chen YC; Chou JM; Letendre L; Li CY
Am J Hematol; 2005 Aug; 79(4):329-31. PubMed ID: 16044436
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
5. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
6. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.
González-Medina I; Bueno J; Torrequebrada A; López A; Vallespí T; Massagué I
Leuk Res; 2002 Sep; 26(9):821-4. PubMed ID: 12127557
[TBL] [Abstract][Full Text] [Related]
7. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of chronic myelomonocytic leukemia.
Catalano L; Improta S; de Laurentiis M; Molica S; Majolino I; Musto P; Fragasso A; De Placido S; Rotoli B
Haematologica; 1996; 81(4):324-9. PubMed ID: 8870376
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic and myeloproliferative disorders in children.
Hasle H
Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
[TBL] [Abstract][Full Text] [Related]
10. The WHO classification of the myelodysplastic syndromes.
Bain B
Exp Oncol; 2004 Sep; 26(3):166-9. PubMed ID: 15494682
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
Occhipinti E; Correa H; Yu L; Craver R
Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukemia: lost in classification?
Bowen DT
Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
[TBL] [Abstract][Full Text] [Related]
13. CMML: a biologically distinct myeloproliferative disease.
Cortes J
Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?
Voglová J; Chrobák L; Neuwirtová R; Malasková V; Straka L
Leuk Res; 2001 Jun; 25(6):493-9. PubMed ID: 11337023
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Beran M; Shen Y; Onida F; Wen S; Kantarjian H; Estey E
Leuk Lymphoma; 2006 Mar; 47(3):417-23. PubMed ID: 16396764
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
17. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
Hasle H; Baumann I; Bergsträsser E; Fenu S; Fischer A; Kardos G; Kerndrup G; Locatelli F; Rogge T; Schultz KR; Starý J; Trebo M; van den Heuvel-Eibrink MM; Harbott J; Nöllke P; Niemeyer CM;
Leukemia; 2004 Dec; 18(12):2008-14. PubMed ID: 15496981
[TBL] [Abstract][Full Text] [Related]
18. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
19. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Phekoo KJ; Richards MA; Møller H; Schey SA;
Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
[TBL] [Abstract][Full Text] [Related]
20. The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
Xicoy B; Triguero A; Such E; García O; Jiménez MJ; Arnán M; Bernal T; Diaz-Beya M; Valcárcel D; Pedro C; Ramos F; Amigo ML; Collado R; Palomo L; Ardanaz MT; Cedena MT; Grau J; Zamora L; Sanz G
Leuk Res; 2018 Jul; 70():34-36. PubMed ID: 29775844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
